<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Calibri Light";
	panose-1:2 15 3 2 2 2 4 3 2 4;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
h1
	{mso-style-link:"Heading 1 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	line-height:107%;
	page-break-after:avoid;
	font-size:16.0pt;
	font-family:"Calibri Light",sans-serif;
	color:#2F5496;
	font-weight:normal;}
h3
	{mso-style-link:"Heading 3 Char";
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	line-height:107%;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Calibri Light",sans-serif;
	color:#1F3763;
	font-weight:normal;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.5in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.5in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
span.Heading1Char
	{mso-style-name:"Heading 1 Char";
	mso-style-link:"Heading 1";
	font-family:"Calibri Light",sans-serif;
	color:#2F5496;}
span.Heading3Char
	{mso-style-name:"Heading 3 Char";
	mso-style-link:"Heading 3";
	font-family:"Calibri Light",sans-serif;
	color:#1F3763;}
.MsoChpDefault
	{font-family:"Calibri",sans-serif;}
.MsoPapDefault
	{margin-bottom:8.0pt;
	line-height:107%;}
@page WordSection1
	{size:595.3pt 841.9pt;
	margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-GB>

<div class=WordSection1>

<h1><span lang=EN-US style='font-size:15.0pt;line-height:107%'>2004A08 Describe
briefly the side effects and complications of heparin therapy.</span></h1>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt'><span
lang=EN-US>&nbsp;</span></p>

<h3><span lang=EN-US style='font-size:13.0pt;line-height:107%'>List:</span></h3>

<p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:22.5pt;margin-bottom:.0001pt;text-indent:-13.5pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Intro</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:22.5pt;margin-bottom:.0001pt;text-indent:-13.5pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Problems</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:22.5pt;margin-bottom:.0001pt;text-indent:-13.5pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Bleeding</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:22.5pt;margin-bottom:.0001pt;text-indent:-13.5pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>HITT</span></p>

<p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:22.5pt;margin-bottom:.0001pt;text-indent:-13.5pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Other (short term and long term)</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt'><span
lang=EN-US>&nbsp;</span></p>

<h3><span lang=EN-US style='font-size:13.0pt;line-height:107%'>Problems that
aren’t side effects:</span></h3>

<table class=MsoTableGrid border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=132 valign=top style='width:98.75pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'><span lang=EN-US>Narrow therapeutic index</span></p>
  </td>
  <td width=469 valign=top style='width:352.05pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:8.3pt;margin-bottom:.0001pt;text-indent:-8.3pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US>Need
  monitoring – aPTT</span></p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:8.3pt;margin-bottom:.0001pt;text-indent:-8.3pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US>Aim
  1.5-2.5x baseline approx</span></p>
  </td>
 </tr>
 <tr>
  <td width=132 valign=top style='width:98.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'><span lang=EN-US>Variable effect</span></p>
  </td>
  <td width=469 valign=top style='width:352.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:8.3pt;margin-bottom:.0001pt;text-indent:-8.3pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US>Variable
  plasma protein concentration</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:8.3pt;margin-bottom:.0001pt;text-indent:-8.3pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US>Zero
  order kinetics at high dose</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:8.3pt;margin-bottom:.0001pt;text-indent:-8.3pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US>Variable
  elimination rate by metabolism (heparinase) &gt; excretion (urine unchanged)</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:8.3pt;margin-bottom:.0001pt;text-indent:-8.3pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US>Heparin
  resistance</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:35.3pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span lang=EN-US style='font-family:"Courier New"'>o<span
  style='font:7.0pt "Times New Roman"'> </span></span><span lang=EN-US>Variation
  in concentration of heparin-binding proteins e.g. albumin</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:35.3pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span lang=EN-US style='font-family:"Courier New"'>o<span
  style='font:7.0pt "Times New Roman"'> </span></span><span lang=EN-US>Accelerated
  clearance: e.g. big pulmonary embolus</span></p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:35.3pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span lang=EN-US style='font-family:"Courier New"'>o<span
  style='font:7.0pt "Times New Roman"'> </span></span><span lang=EN-US>Acquired
  AT3 deficiency (e.g. liver failure)</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt'><span
lang=EN-US>&nbsp;</span></p>

<h3><span lang=EN-US style='font-size:13.0pt;line-height:107%'>Bleeding:
*Dose-dependent*</span></h3>

<table class=MsoTableGrid border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=84 valign=top style='width:62.75pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'><span lang=EN-US>Risk</span></p>
  </td>
  <td width=517 valign=top style='width:388.05pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:8.3pt;margin-bottom:.0001pt;text-indent:-8.3pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US>1-5%
  if therapeutic anticoagulation</span></p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:8.3pt;margin-bottom:.0001pt;text-indent:-8.3pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US>e.g.
  peptic ulcer bleed, haemorrhagic stroke</span></p>
  </td>
 </tr>
 <tr>
  <td width=84 valign=top style='width:62.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'><span lang=EN-US>Mechanism</span></p>
  </td>
  <td width=517 valign=top style='width:388.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:8.3pt;margin-bottom:.0001pt;text-indent:-8.3pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US>Heparin
  binds and potentiates AT3</span></p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:8.3pt;margin-bottom:.0001pt;text-indent:-8.3pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US>AT3
  inactivates IIa, Xa, IXa, XIa, VIIa-TF</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt'><span
lang=EN-US>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt'><span
lang=EN-US>&nbsp;</span></p>

<h3><span lang=EN-US style='font-size:13.0pt;line-height:107%'>HITT:
*Idiosyncratic*</span></h3>

<table class=MsoTableGrid border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=84 valign=top style='width:62.75pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'><span lang=EN-US>Risk</span></p>
  </td>
  <td width=517 valign=top style='width:388.05pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:8.0pt;margin-bottom:.0001pt;text-indent:-8.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US>1
  in 200 therapeutic doses</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:8.0pt;margin-bottom:.0001pt;text-indent:-8.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US>1
  in 10,000 prophylactic doses</span></p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:8.0pt;margin-bottom:.0001pt;text-indent:-8.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US>UFH
  &gt;&gt; LMWH</span></p>
  </td>
 </tr>
 <tr>
  <td width=84 valign=top style='width:62.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'><span lang=EN-US>Type 1 </span></p>
  </td>
  <td width=517 valign=top style='width:388.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:8.0pt;margin-bottom:.0001pt;text-indent:-8.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US>95-99%</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:8.0pt;margin-bottom:.0001pt;text-indent:-8.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US>&#8595;Platelet
  count by &lt;10%</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:8.0pt;margin-bottom:.0001pt;text-indent:-8.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US>Onset
  &lt;4 days</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:8.0pt;margin-bottom:.0001pt;text-indent:-8.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US>Non
  immune-mediate</span></p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:8.0pt;margin-bottom:.0001pt;text-indent:-8.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US>Low
  risk complications</span></p>
  </td>
 </tr>
 <tr>
  <td width=84 valign=top style='width:62.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'><span lang=EN-US>Type 2</span></p>
  </td>
  <td width=517 valign=top style='width:388.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:8.0pt;margin-bottom:.0001pt;text-indent:-8.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US>1-5%
  (&lt;1% LMWH))</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:8.0pt;margin-bottom:.0001pt;text-indent:-8.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US>Onset
  4-14 days</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:8.0pt;margin-bottom:.0001pt;text-indent:-8.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US>&#8595;Platelet
  count by &gt;50% or to &lt;150</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:8.0pt;margin-bottom:.0001pt;text-indent:-8.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US>Immune-mediated;
  IgG binds heparin + PF4 = hapten</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:8.0pt;margin-bottom:.0001pt;text-indent:-8.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US>Platelet
  activation and aggregation, thrombosis</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:8.0pt;margin-bottom:.0001pt;text-indent:-8.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US>50%
  risk major thrombotic event: ATE, VTE</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:8.0pt;margin-bottom:.0001pt;text-indent:-8.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US>Risk
  major bleeding: haemorrhagic stroke, classic bilateral adrenal haemorrhage</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:8.0pt;margin-bottom:.0001pt;text-indent:-8.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US>Death
  10-30%</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:8.0pt;margin-bottom:.0001pt;text-indent:-8.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US>Diagnosis:
  “4Ts”, heparin/PF4 assay</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:8.0pt;margin-bottom:.0001pt;text-indent:-8.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US>Rx:
  stop offender; start alternative e.g. lepirudin, argatroban</span></p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:8.0pt;margin-bottom:.0001pt;text-indent:-8.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US>Do
  NOT start warfarin; risk skin necrosis, limb gangrene</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt'><span
lang=EN-US>&nbsp;</span></p>

<h3><span lang=EN-US style='font-size:13.0pt;line-height:107%'>Other side
effects: (UFH &gt; LMWH &gt; Fondaparinux):</span></h3>

<table class=MsoTableGrid border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=90 valign=top style='width:67.25pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'><span lang=EN-US>Short term</span></p>
  </td>
  <td width=511 valign=top style='width:383.55pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:8.0pt;margin-bottom:.0001pt;text-indent:-8.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US>Hypotension
  (if rapid injection) – vasodilatation, venodilatation</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:8.0pt;margin-bottom:.0001pt;text-indent:-8.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US>Hypersensitivity</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:8.0pt;margin-bottom:.0001pt;text-indent:-8.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US>Hepatotoxicity</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:8.0pt;margin-bottom:.0001pt;text-indent:-8.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US>Suppression
  of aldosterone synthesis, &#8593;K<sup>+</sup></span></p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:8.0pt;margin-bottom:.0001pt;text-indent:-8.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US>Skin
  necrosis</span></p>
  </td>
 </tr>
 <tr>
  <td width=90 valign=top style='width:67.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'><span lang=EN-US>Long term</span></p>
  </td>
  <td width=511 valign=top style='width:383.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:8.0pt;margin-bottom:.0001pt;text-indent:-8.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US>Osteoporosis</span></p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:8.0pt;margin-bottom:.0001pt;text-indent:-8.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US>Alopecia</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt'><span
lang=EN-US>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt'><span
lang=EN-US>&nbsp;</span></p>

</div>

</body>

</html>
